AI Can Predict Response to Early Sertraline for Chronic Major Depression
By Lori Solomon HealthDay Reporter
WEDNESDAY, Feb. 14, 2024 -- Early sertraline treatment response can be predicted using neuroimaging and clinical data in outpatients with chronic major depressive disorder, according to a study published online Feb. 7 in The American Journal of Psychiatry.
Maarten G. Poirot, from University of Amsterdam, and colleagues assessed whether a multimodal machine learning approach could predict early sertraline response in patients with major depressive disorder. The analysis included 229 adult outpatients with unmedicated recurrent or chronic major depressive disorder who underwent magnetic resonance neuroimaging and had clinical data collected before and one week after treatment.
The researchers found that internal cross-validation performance was significantly better than chance in predicting response to sertraline (balanced accuracy [bAcc], 68 percent; area under the receiver operating characteristic curve [AUROC], 0.73). Using external cross-validation on data from placebo nonresponders (bAcc, 62 percent; AUROC, 0.66) and placebo nonresponders who were switched to sertraline (bAcc, 65 percent; AUROC, 0.68) resulted in differences that suggest specificity for sertraline treatment versus placebo treatment.
"This is important news for patients. Normally, it takes six to eight weeks before it is known whether an antidepressant will work," coauthor Liesbeth Reneman, M.D., Ph.D., also from University of Amsterdam, said in a statement. "With this method, we can already prevent two-thirds of the number of 'erroneous' prescriptions of sertraline and thus offer better quality of care for the patient. Because the drug also has side effects."
Several authors disclosed ties to the pharmaceutical or medical technology industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Perinatal Suicide Tied to Intimate Partner Problems, Depression, Substance Use
WEDNESDAY, July 3, 2024 -- Perinatal suicide is often associated with intimate partner problems (IPPs) and behavioral health issues, according to a study published online...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.